in vivo – Talk Bio

Editas Medicine Reboots With Cholesterol Gene Therapy (EDIT-401) as Lead Asset

1 week ago talkbio0Tagged Clinical Development, EDIT-401, Editas Medicine, Gene Modification, gene therapy, Hyperlipidemia, in vivo, LDL Cholesterol Lipoproteins, LDLR gene, strategic pivot

Editas Medicine; EDIT-401; gene therapy; hyperlipidaemia; LDL cholesterol; LDLR gene; in vivo gene editing; strategic pivot; clinical development

Gilead’s Kite to Acquire Interius for $350M, Advancing In Vivo CAR-T Therapy

3 weeks ago talkbio0Tagged Acquisition, CAR-T, CAR-T therapy, Cell Therapy, Gilead, in vivo, Interius BioTherapeutics, Kite, device (physical object), Tecartus, Yescarta

Gilead; Kite; Interius BioTherapeutics; CAR-T therapy; in vivo CAR-T; acquisition; off-the-shelf cell therapy; $350 million; biotech; Yescarta; Tecartus; cell therapy platform

Flagship’s Sail Biomedicines announces second round of layoffs in 2025

2 months ago talkbio0Tagged CAR-T, eRNA, Flagship, Immunology pipeline, in vivo, layoffs, Pioneering, RNA, Sail Biomedicines

Sail Biomedicines; Flagship Pioneering; layoffs; immunology pipeline; endless RNA; eRNA; in vivo CAR-T; biotech workforce reduction

AstraZeneca deepens cell therapy expansion with $1B EsoBiotec buyout

6 months ago talkbio0Tagged Acquisition, AstraZeneca, Autoimmune Diseases, Cell Engineering, Cell Therapy, ENaBL Platform, EsoBiotec, in vivo, Neoplasms

AstraZeneca, EsoBiotec, cell therapy, acquisition, ENaBL platform, in vivo cell engineering, oncology, autoimmune diseases